In the clinical trial with BIA-10-2474, a fatty acid amide hydrolase (FAAH)-inhibitor in development for diseases in which elevated endocannabinoid tone might be beneficial such as pain, glaucoma and post-traumatic stress disorder, several subjects developed neurological damage and one subject died [13]. The gene discussed is FAAH; the disease is glaucoma.